الفهرس 
Acute myocardial infractionOnly 14 pages are availabe for public view
 |  | from | 78 |  |  |
| | | from | 78 | | |
Abstract
The diagnosis or exclusion of AMI as early as possible after admission to the emergency unit is essential for good prognosis. New and expensive biochemical tests have been developed and are used for this purpose Important characteristics determining the utility of biochemical markers are its cellular localization, aqueous solubility, clearance from the circulation, specificity for myocardium, and detectability in plasma. During the last 20 years, many scientific groups have been searching for diagnostic biomarkers other than troponins that can predict ischemic myocardial injury. The scope of biomarkers in cardiovascular medicine has widened in recent years and a number of novel biomarkers have been evaluated as alternative markers for their incremental value, in the risk stratification of patients with possible ACS. These novel biomarkers reflect different aspects of the pathophysiology in patients with ACS and therefore have the potential to identify defined pathological processes which might be amenable to specific therapies and, moreover, may provide complementary information when measured in conjunction with each other. Heart-type Fatty acid binding protein (H-FABP) is a newly introduced plasma marker of acute myocardial infarction (AMI). The plasma kinetics of H-FABP (15KD) closely resemble those of myoglobin (18KD) in that elevated plasma concentrations are found within 3 h after AMI and return to normal generally within 12 to 24 h. This makes both myoglobin and H-FABP useful biochemical markers for the early assessment or exclusion of AMI.